August 23, 2024 07:00 AM EDT
Peer Review

Gen­mab makes two C-suite ad­di­tions as COO leaves; James Sabry leads a re­vamped sup­port­ing cast at Bio­Marin

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ There are sub­stan­tial lead­er­ship changes at Gen­mab, start­ing with the de­par­ture of COO An­tho­ny Manci­ni. Peer Re­view

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

Phar­ma tar­iffs could leave lit­tle room to hide with sweep­ing probe un­der­way

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times